H ong Kong is to take part in two
global studies involving a new
targeted therapy for breast cancer
that over expresses the human epidermal
growth factor receptor 2 (HER2),
researchers announced.
Approximately 3,424 patients will be
enrolled globally in these randomized,
double-blind, multicenter, placebocontrolled
phase III studies to evaluate